OM:PLED

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

PledPharma AB, a pharmaceutical company, develops pharmaceuticals for the treatment of debilitating and life-threatening medical conditions.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has PledPharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PLED's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.1%

PLED

-0.8%

SE Biotechs

5.1%

SE Market


1 Year Return

-69.3%

PLED

7.2%

SE Biotechs

10.9%

SE Market

Return vs Industry: PLED underperformed the Swedish Biotechs industry which returned 10.4% over the past year.

Return vs Market: PLED underperformed the Swedish Market which returned 11.2% over the past year.


Shareholder returns

PLEDIndustryMarket
7 Day-3.1%-0.8%5.1%
30 Day3.1%5.3%14.4%
90 Day-15.0%20.8%5.5%
1 Year-69.3%-69.3%8.0%7.2%12.5%10.9%
3 Year-46.6%-46.6%25.3%22.3%17.6%1.7%
5 Year-81.6%-81.6%78.9%67.3%38.3%11.0%

Price Volatility Vs. Market

How volatile is PledPharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PledPharma undervalued compared to its fair value and its price relative to the market?

1.49x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PLED's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PLED's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PLED is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: PLED is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PLED's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PLED is good value based on its PB Ratio (1.5x) compared to the SE Biotechs industry average (6.2x).


Next Steps

Future Growth

How is PledPharma forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

84.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PLED is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PLED is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PLED is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PLED's revenue (24% per year) is forecast to grow faster than the Swedish market (5.8% per year).

High Growth Revenue: PLED's revenue (24% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PLED is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has PledPharma performed over the past 5 years?

-14.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PLED is currently unprofitable.

Growing Profit Margin: PLED is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PLED is unprofitable, and losses have increased over the past 5 years at a rate of -14.4% per year.

Accelerating Growth: Unable to compare PLED's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PLED is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).


Return on Equity

High ROE: PLED has a negative Return on Equity (-62.92%), as it is currently unprofitable.


Next Steps

Financial Health

How is PledPharma's financial position?


Financial Position Analysis

Short Term Liabilities: PLED's short term assets (SEK233.9M) exceed its short term liabilities (SEK32.0M).

Long Term Liabilities: PLED's short term assets (SEK233.9M) exceed its long term liabilities (SEK29.0K).


Debt to Equity History and Analysis

Debt Level: PLED is debt free.

Reducing Debt: PLED has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PLED has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PLED has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 15.1% each year.


Next Steps

Dividend

What is PledPharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PLED's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PLED's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PLED's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PLED's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PLED's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

14.4yrs

Average management tenure


CEO

Nicklas Westerholm (43yo)

3yrs

Tenure

kr3,301,000

Compensation

Mr. Nicklas Westerholm has been the Chief Executive Officer of PledPharma AB since June 16, 2017. Mr. Westerholm has been working in the AstraZeneca Group since 1995 in several global roles and different b ...


CEO Compensation Analysis

Compensation vs Market: Nicklas's total compensation ($USD358.63K) is above average for companies of similar size in the Swedish market ($USD222.97K).

Compensation vs Earnings: Nicklas's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Nicklas Westerholm
Chief Executive Officer3yrskr3.30m0.030% SEK89.8k
Torsten Almén
14.42yrsno datano data
Ingemar Lundström
14.42yrsno datano data
Louis Ignarro
14.42yrsno datano data
Heidi Brurok
14.42yrsno datano data
Rob Towart
14.42yrsno datano data
Yilmaz Mahshid
Chief Financial Officer2.5yrsno data0.030% SEK89.8k
Jacques Näsström
Chief Scientific Officerno datakr655.00k0.15% SEK451.3k
Stefan Carlsson
Chief Medical Officer2.58yrsno datano data

14.4yrs

Average Tenure

59.5yo

Average Age

Experienced Management: PLED's management team is seasoned and experienced (14.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Håkan Åström
Independent Chairman9.42yrskr600.00k0.94% SEK2.8m
Sten Nilsson
Independent Director7.42yrskr165.00k0.0021% SEK6.2k
Marie Tragardh
Independent Director3.17yrskr165.00kno data
Bengt Glimelius
Member of Scientific Advisory Board2.83yrsno datano data
Gunilla Osswald
Independent Director3.42yrskr165.00kno data
Elisabeth Svanberg
Independent Director3.42yrskr165.00kno data
Guido Cavaletti
Member of Scientific Advisory Board2.83yrsno datano data
David Cella
Member of Scientific Advisory Board2.83yrsno datano data
Rolf Karlsten
Member of Scientific Advisory Board2.83yrsno datano data
Laura James
Member of Scientific Advisory Board2yrsno datano data

3.0yrs

Average Tenure

58yo

Average Age

Experienced Board: PLED's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PLED insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10%.


Top Shareholders

Company Information

PledPharma AB's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PledPharma AB
  • Ticker: PLED
  • Exchange: OM
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr300.322m
  • Shares outstanding: 53.53m
  • Website: https://pledpharma.com

Number of Employees


Location

  • PledPharma AB
  • Grev Turegatan 11 C
  • Stockholm
  • Stockholm County
  • 114 46
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PLEDOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKApr 2011
P0FBST (Boerse-Stuttgart)YesShare CapitalDEEURApr 2011
P0FDB (Deutsche Boerse AG)YesShare CapitalDEEURApr 2011

Biography

PledPharma AB, a pharmaceutical company, develops pharmaceuticals for the treatment of debilitating and life-threatening medical conditions. It is developing PledOx, which is in Phase III clinical trial to protect patients with colorectal cancer against Cellgiftsinducerad peripheral neuropathy, a disabling effect of chemotherapy treatment; and Aladote to reduce acute liver failure damage caused by acetaminophen/paracetamol poisoning. The company was founded in 2006 and is headquartered in Stockholm, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 23:10
End of Day Share Price2020/06/05 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.